Market Size of Global Myeloproliferative Disorders (MPD) Treatment Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 4.90 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Myeloproliferative Disorders Treatment Market Analysis
The myeloproliferative disorders (MPD) treatment market is expected to register a CAGR of 4.9% over the forecast period.
The outbreak of the COVID-19 pandemic has pushed the pharmaceutical industry into action, with a race to develop both therapeutic and preventive drugs. Exponentially increasing cases of the coronavirus worldwide are leading to the need for the development of novel treatments, with several clinical trials underway. Meanwhile, the manufacturers of myeloproliferative disorders (MPD) treatment drugs focused on developing biological vaccines and drugs, which can also be applied in diagnosing and treating COVID-19.
The outbreak of the pandemic positively impacted the market as it increased the cases of chronic myeloproliferative neoplasm (MPN) and associated disorders. For instance, according to the American Society of Hematology article published in September 2021, people suffering from intermediate 2 or high-risk myelofibrosis were expected to have a higher risk of adverse outcomes if they get infected with COVID-19. It also stated that thromboembolic (TE) complications were increasing in patients who had suffered from COVID-19, especially in the advanced stages of the disease. Increased risk of thromboembolic (TE) complications with COVID-19 emerged as a serious concern for myeloproliferative neoplasms patients due to the pre-existing risk for disease associated with thrombotic and/or hemorrhagic complications. Therefore, such an increase in myeloproliferative disorder (MPD) cases had lead to an increase of treatment rates. Thus, the market witnessed a positive impact during the pandemic.
The increasing research and development investments for developing novel treatments and strong presence of pipeline drugs are the major factors propelling the market growth. For instance, according to the report published by the European Commission in December 2021, the European Union-based companies increased their investments in research and development in the health upto 10.3%. It also reported that companies in the United States and China increased their overall research and development investments by 9.1% and 18.1% respectively. The United States and China-based companies have expanded their share of research and development in healthcare sector during the coronavirus crisis, in which United States increased upto 17.9% and China increased upto 30.7%. Therefore, such a scenario is anticipated to accelerate the research works related to diseases, clinical trials, and novel treatments for combatting disorders. Furthermore, increasing cases of myeloproliferative disorders is also one of the major driving factors for the market. For instance, according to the study titled, "Myeloproliferative Neoplasms" published in May 2022, myeloproliferative neoplasms were more common in males, with an incidence rate of about 2.4 new cases per 100,000 versus 1.4 new cases per 100,000 in females. Therefore, owing to such instances considerable market growth is expected over the forecast period.
However, side effects associated with medications is likely to hinder the market growth over the forecast period.
